

# **Product Introduction**

# **OSI-930**

OSI-930 is a potent inhibitor of **Kit**, **KDR** and **CSF-1R** with **IC50** of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRa/ $\beta$ , Flt-3 and Abl. Phase 1.

#### Technical Data:

Molecular Weight (MW):	443.44	
Formula:	C22H16F3N3O2S	
Solubility (25°C)	DMSO 89 mg/mL	
* <1 mg/ml means Water <1 mg/mL slightly	Water <1 mg/mL	N I
soluble or insoluble:	Ethanol 3 mg/mL	NH FF
Purity:	>98%	
Storage:	3 years -20°C Powder	0 \F
	6 months-80℃in DMSO	
CAS No.:	728033-96-3	

## **Biological Activity**

OSI-930 inhibits the cell proliferation in the HMC-1 cell line with IC50 of 14 nM without significant effect on growth of the COLO-205 cell line that does not express a constitutively active mutant receptor tyrosine kinase. Moreover, OSI-930 also induces apoptosis in HMC-1 cell line with EC50 of 34 nM. [1] A recent study shows that OSI-930 inactivates purified, recombinant cytochrome P450 (P450) 3A4 with a Ki of 24  $\mu$ M in a time- and concentration-dependent mode. [2]

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

OSI-930, administrated at the maximally efficacious dose of 200 mg/kg by oral gavage, exhibits potent antitumor activity in a broad range of preclinical xenograft models including HMC-1, NCI-SNU-5, COLO-205 and U251 xenograft models. [1]

### References

- [1] Garton AJ, et al. Cancer Res. 2006, 66(2):1015-1024.
- [2] Lin HL, et al. Drug Metab Dispos. 2011, 39(2), 345-350.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

